The project is born out of a concrete demand within the pharma supply chain to provide a hi-tech solution to tackle the problem of limited-supply and out-of-stock medicine.
From 2028, it will be mandatory to notify intra-EU B2B transactions. Member states have begun the "race to compliance," and Italian companies will need to follow the regulatory developments of the countries where their business partners are located.